english.prescrire.org > Prescrire International > N°246 - March 2023

n°246

March 2023

Issue Contents
Editorial

Free  Negligence

p.59

Marketing Authorisations


Delamanid (Deltyba°) in pulmonary multidrug-resistant tuberculosis in children and adolescents

p.61

Empagliflozin (Jardiance°) in chronic heart failure

p.62-63
A second gliflozin in cardio­logy, without any demonstrated advantages

Vericiguat (Verquvo°) in chronic heart failure after decompensation

p.64-65
No reduction in mortality or improvement in quality of life

Tofacitinib (Xeljanz°) in juvenile idiopathic arthritis

p.66

Elasomeran (Spikevax°) and covid-19 in children aged 6 to 11 years

p.67

Inactivated, adjuvanted covid-19 vaccine (Covid-19 vaccine Valneva°) for adults under 50 years of age

p.68

Satralizumab (Enspryng°) in neuro­myelitis optica

p.69

Pralsetinib (Gavreto°) in metastatic lung cancer with RET mutation

p.70

Naldemedine (Rizmoic°) in opioid-induced constipation

p.71

Pegcetacoplan (Aspaveli°) in paroxysmal nocturnal haemoglobinuria after failure of a C5 complement inhibitor

p.72

Rucaparib in relapsed ovarian cancer: a recklessly approved indication revoked

p.73

Editors' opinion. Winners and losers

p.73

Sofosbuvir + velpatasvir + voxilaprevir (Vosevi°) for hepatitis C in adolescents

p.74

Adverse Effects


Oral vitamin D supplementation: dangerous overdoses caused by errors

p.75-77

Anagrelide: thrombosis following discontinuation

p.77

Topiramate during pregnancy: autism and intellectual disability in children (continued)

p.78

Olanzapine, clozapine, quetiapine: gestational diabetes

p.78

Common stem: -reotide

p.79

Common stem: -grel

p.79

Outlook


Free  2022 Prescrire Drug Awards

p.80

Free  The Prescrire awards for 2022

p.80-81

Free  2022 Information Awards

p.81

Consultation on proprietary drug names

p.82

US court orders FDA to hasten release of data on a covid-19 vaccine

p.82-83

Depakine°, France's first class-action lawsuit involving a health product

p.83

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe